Gibson Dunn is providing advisory services for 89bio, Inc., a clinical-stage biopharmaceutical business that specializes in the creation and marketing of novel treatments for liver and cardiometabolic disorders, as it prepares to sell to Roche Holdings, Inc. for up to $3.5 billion.